Recent Progress in Development of Polo-Like Kinase 1 Inhibitors: Efforts So Far

Polo-like kinase 1(Plk1) plays an important role in the inhibition of cell proliferation and which is come under the family of serine/threonine-protein kinase. Which is a highly specific target for cancer therapy. In some clinical studies, Plk1 has been identified as a target for cancer. Currently,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ramesh L. Sawant, Jyoti B. Wadekar, Rushikesh D. Ukirde, Ganesh D. Barkade
Formato: article
Lenguaje:EN
Publicado: Tabriz University of Medical Sciences 2021
Materias:
Acceso en línea:https://doaj.org/article/0a9f7fde490847278b7fe11ff030ad94
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Polo-like kinase 1(Plk1) plays an important role in the inhibition of cell proliferation and which is come under the family of serine/threonine-protein kinase. Which is a highly specific target for cancer therapy. In some clinical studies, Plk1 has been identified as a target for cancer. Currently, so many scientists are working on the development of the Plk1 inhibitors and so many scientists and researchers thinking about working on it. Recent strategy for Plk1 inhibition is the development of small molecule inhibitors which will inhibit the Plk1 through the ATP-binding site of the Plk. Now new generation Plk1 inhibitors being tested clinically which are targeting polo box domain. This review highlights the recent progress made in the development of Plk1 inhibitors as anticancer agents.